Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04022239
Other study ID # 2018-0972
Secondary ID NCI-2019-0390020
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 13, 2020
Est. completion date July 31, 2025

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact Issa F. Khouri, M D
Phone 713-745-0049
Email ikhouri@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy and total body irradiation before or after a stem cell transplant helps kills cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Sometimes, the transplanted cells from a donor can attack the body's normal cells called GVHD. Giving tacrolimus, mycophenolate mofetil, and filgrastim after the transplant may stop this from happening.


Description:

PRIMARY OBJECTIVE: I. Evaluate the safety of substituting the standard post-transplant cyclophosphamide (PT-CY) given on day +3 and +4 with post-transplant bendamustine (PT-BEN) in patients undergoing HLA-mismatched hematopoietic cell transplantation. SECONDARY OBJECTIVES: I. To evaluate treatment-related mortality. II. To assess acute and chronic graft-versus-host disease (GVHD). III. To assess overall survival, progression-free survival and relapse rates. IV. To evaluate the risk of acute cystitis. V. To evaluate immune reconstitution after transplantation. OUTLINE: This is a dose-escalation study of bendamustine. Patients are assigned to 1 of 2 treatment schedules. SCHEDULE I (NON-LYMPHOMA): Patients receive fludarabine intravenously (IV) over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo total body irradiation (TBI) on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by orally (PO) once daily (QD) or twice daily (BID) for 6 months and mycophenolate mofetil PO thrice daily (TID) until day 100. Beginning day 7, patients receive filgrastim-sndz subcutaneously (SC) QD until blood cell levels return to normal. SCHEDULE II (LYMPHOID MALIGNANCIES): Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8. After completion of study treatment, patients are followed weekly for 3 months, every 3 months in year 1, and every 6 months in year 2.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date July 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patient with hematologic malignancies. - Donor: Matched sibling, matched unrelated, mismatched or haploidentical - Zubrod performance 0 to 2 or Karnofsky of at least 60. - Creatinine less than or equal to 1.6 mg/dL and creatinine clearance >/= 30 ml/min. Creatine clearance will be calculated using the Cockcroft-Gault equation. (at time of study entry) - Total bilirubin less than < 1.5 x upper limit of normal (UNL). (at time of study entry) - Serum glutamate pyruvate transaminase (SGPT) < 2.5 x ULN. (at time of study entry) - Ejection fraction >= 40%. (at time of study entry) - Forced expiratory volume in one second (FEV1) >/= 40%. (at time of study entry) - Forced vital capacity (FVC) >/= 40%. (at time of study entry) - Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40%. (at time of study entry) Exclusion Criteria: - Pregnant or nursing women. - Known to be human immunodeficiency virus (HIV) positive. - Active and uncontrolled disease/infection. - Unable or unwilling to sign consent. - Current active hepatic or biliary disease (with exception of Gilbert's syndrome). - Active hepatitis B or C. - Toxicities (grade > 1) unresolved from prior treatment (including chemotherapy, targeted therapy, immunotherapy, experimental agents radiation, or surgery. - Patients with standard risk acute leukemia in first complete remission and patients with chronic myeloid leukemia in first chronic will be excluded during escalated phase.

Study Design


Related Conditions & MeSH terms

  • Hematopoietic and Lymphoid System Neoplasm

Intervention

Procedure:
Allogeneic Hematopoietic Stem Cell Transplantation
Undergo stem cell transplantation
Drug:
Bendamustine
Given IV
Cyclophosphamide
Given IV
Biological:
Filgrastim-sndz
Given SC
Drug:
Fludarabine
Given IV
Melphalan
Given IV
Mycophenolate Mofetil
Given PO
Biological:
Rituximab
Given IV
Drug:
Tacrolimus
Given IV and PO
Radiation:
Total-Body Irradiation
Undergo TBI

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose level (MTDL) (Phase I) Will employ the time-to-event Bayesian optimal interval design to find the MTDL. After the trial is completed, the MTDL will be selected based on isotonic regression as specified in Yuan et al. Specifically, MTDL will be selected as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate. If there are ties, the higher dose level when the isotonic estimate is lower than the target toxicity rate will be selected and the lower dose level when the isotonic estimate is greater than or equal to the target toxicity rate will be selected. Up to 30 days
Primary Dose-limiting toxicity (Phase I) Up to 100 days
Primary Incidence of adverse events (Phase II) The trial is continuously monitored for toxicity per the statistical design. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Completed NCT04938869 - Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer N/A
Active, not recruiting NCT04436835 - Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress N/A
Enrolling by invitation NCT06104657 - Qualitative Techniques to Define Meaningful Within-Patient Change in Symptoms of Advanced Cancer Patients
Recruiting NCT05878405 - Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer Phase 3
Recruiting NCT06063603 - Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study N/A
Recruiting NCT05564468 - Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer N/A
Active, not recruiting NCT05868486 - Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer Early Phase 1
Recruiting NCT05997589 - Financial Health Educational Program for Increasing Financial Literacy Among Underserved Communities in Western New York N/A
Recruiting NCT04572815 - Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant Phase 2
Recruiting NCT04494945 - Identifying and Caring for Individuals With Inherited Cancer Syndrome N/A
Recruiting NCT05346692 - Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer Early Phase 1
Withdrawn NCT05589844 - A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Recruiting NCT03471260 - Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT05844306 - RefleXion PET/CT Imaging Performance in Patients With Various Malignancies N/A
Recruiting NCT06073951 - Evaluation of a Couple-Based Physical Activity Intervention N/A
Suspended NCT05515692 - Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease Early Phase 1

External Links